

Cardiff University and Hbt entering an exclusive deal for factor H variant assay (April 2009).

Hbt has obtained the exclusive rights from Cardiff University for the development of a factor H variant (Y402/H402) research assay. This unique tool is developed in close collaboration between Prof. Paul Morgan (dept. Medical Biochemistry and Immunology) at Cardiff University and the R&D department of Hbt and is developed within 5 months after signing the agreement.

Loek Willems, Business Developer at Hbt: “Co-development of reagents that make a difference for scientific research is our main goal. Since Y402H polymorphism in the complement regulator factor H (fH) is strongly associated with age-related macular degeneration (AMD) the assay will be of high value for research on AMD.”

Paul Morgan: “After a long and hard struggle to generate these unique reagents, we are delighted to see them evolve so quickly into a research tool available to the wider community. This would not have been possible without the excellent collaboration with Hbt who have been superb partners throughout the process. I hope that this research tool will help those researching roles of fH in AMD and other diseases. We look forward to future collaborations that might yield a clinical assay to aid patient diagnosis and management.”

For more information regarding fH variant assay, [click here](#).

About Hbt:

Hycult biotechnology (Hbt) is specialized in developing and manufacturing high quality antibodies, proteins/peptides and a wide variety of assays for biomedical research. As a leader in niche markets in the field of immunology and cell biology, Hbt develops and manufactures antibodies, assays and new technologies that fulfill the needs and demands of the research community. Hbt has ample experience in assay development, especially for innate immune proteins. Hbt was ISO 9001:2000 certified in 1998 and has been upgraded to EN ISO 13485:2003 in 2007. Hbt will launch its first CE-labeled assay in 2009.

If you as scientist are interested in a collaboration or commercialization of any of your reagents please contact Loek Willems at: l.willems@hbt.nl.